NCT07265752

Tirzepatide for the Treatment of Cannabis Use Disorder

Tirzepatide for the Treatment of Cannabis Use Disorder: A Pilot Double-blind, Placebo-controlled, Crossover Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 6 (estimated)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder.

Detailed description

This is a pilot randomized cross-over trial to examine the effects of tirzepatide on cue-reactivity among individuals with cannabis use disorder. Eligible participants will be scheduled in random order to receive either tirzepatide or placebo injection in double-blind fashion and cross-over design. Outcomes will be assessed at the following study visit. Washout period of at least 4 weeks will be required between tirzepatide or placebo injections. Primary outcome of interest is cue-induced craving to cannabis-related visual cues.

Conditions

• Cannabis Use Disorder

Interventions

Type	Name	Description
DRUG	Tirzepatide	2.5mg subcutaneous injection once
DRUG	Placebo	Saline placebo subcutaneous injection once

Timeline

• Start date: 2026-07-01
• Primary completion: 2028-06-30
• Completion: 2028-06-30
• First posted: 2025-12-05
• Last updated: 2025-12-18

Regulatory

• FDA-regulated drug study